CSBR Key Statistics, Chart & Performance
The current stock price of CSBR is 6.54 USD. In the past month the price decreased by -3.96%. In the past year, price increased by 44.69%.
CSBR Latest News, Press Relases and Analysis
CSBR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.38 | 221.98B | ||
| DHR | DANAHER CORP | 29.41 | 160.19B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.73 | 56.74B | ||
| A | AGILENT TECHNOLOGIES INC | 27.51 | 43.52B | ||
| IQV | IQVIA HOLDINGS INC | 19.78 | 39.17B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.29 | 30.17B | ||
| WAT | WATERS CORP | 31.77 | 24.02B | ||
| ILMN | ILLUMINA INC | 30.15 | 20.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.21 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.43 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 13.86B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B |
Related stock screener links
About CSBR
Company Profile
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
Company Info
CHAMPIONS ONCOLOGY INC
One University Plaza,, Suite 307
Hackensack NEW JERSEY 07601 US
CEO: Ronnie Morris
Employees: 210
Phone: 12018088400
CHAMPIONS ONCOLOGY INC / CSBR FAQ
What does CSBR do?
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
What is the current price of CSBR stock?
The current stock price of CSBR is 6.54 USD. The price increased by 0.62% in the last trading session.
Does CSBR stock pay dividends?
CSBR does not pay a dividend.
How is the ChartMill rating for CHAMPIONS ONCOLOGY INC?
CSBR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is CHAMPIONS ONCOLOGY INC (CSBR) stock traded?
CSBR stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of CSBR stock?
CHAMPIONS ONCOLOGY INC (CSBR) operates in the Health Care sector and the Life Sciences Tools & Services industry.
Is CHAMPIONS ONCOLOGY INC (CSBR) expected to grow?
The Revenue of CHAMPIONS ONCOLOGY INC (CSBR) is expected to grow by 5.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CSBR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CSBR. When comparing the yearly performance of all stocks, CSBR is one of the better performing stocks in the market, outperforming 85.03% of all stocks.
CSBR Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CSBR. Both the profitability and the financial health of CSBR get a neutral evaluation. Nothing too spectacular is happening here.
CSBR Financial Highlights
Over the last trailing twelve months CSBR reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 289.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.19% | ||
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| Debt/Equity | 0.02 |
CSBR Forecast & Estimates
7 analysts have analysed CSBR and the average price target is 12.24 USD. This implies a price increase of 87.16% is expected in the next year compared to the current price of 6.54.
For the next year, analysts expect an EPS growth of -50.13% and a revenue growth 5.84% for CSBR